stockrowBridgeBio Pharma, Inc.
BBIO Healthcare Biotechnology
BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.
- Revenue
- +192.6%
- EPS
- +55.8%
- Free cash flow
- +60.5%
- Total debt
- +4.21%
Quarter to September 2026, against a year earlier
Follow BBIO
Alert me
BridgeBio Pharma, Inc. (BBIO) Revenue growth
BridgeBio Pharma, Inc.'s revenue growth over the twelve months to 30 September 2026 was 167.3%, up 41.0 percentage points from fiscal 2025 (126.3%). Over the past ten years it has ranged from −88.0% (fiscal 2023) to 2,285.3% (fiscal 2024); the current reading is higher than 57% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 126.3% | (2,159.01) |
| FY2024 | 2,285.3% | 2,373.29 |
| FY2023 | −88.0% | (99.40) |
| FY2022 | 11.4% | (733.76) |
| FY2021 | 745.1% | 824.80 |
| FY2020 | −79.7% | (471.36) |
| FY2019 | 391.7% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 192.6% | 72.21 |
| Jun 2026 | 120.4% | 53.61 |
| Mar 2026 | 66.8% | (2,454.40) |
| Dec 2025 | 2,521.2% | (1,796.83) |
| 23 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| BBIO BridgeBio Pharma, Inc. | 167.3% |
| KYMR Kymera Therapeutics, Inc. compare | 134.8% |
| ASND Ascendis Pharma A/S compare | 126.0% |
| HALO Halozyme Therapeutics, Inc. compare | 45.0% |
| BMRN BioMarin Pharmaceutical Inc. compare | 18.1% |
| JAZZ Jazz Pharmaceuticals PLC compare | 13.5% |
| EXEL Exelixis, Inc. compare | 9.12% |
| TECH Bio-Techne Corp compare | −0.38% |
| SMMT Summit Therapeutics PLC compare | −61.0% |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on BBIO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement